PMID- 35399718
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 13
IP  - 6
DP  - 2022
TI  - An insulin growth factor-I/II-neutralizing monoclonal antibody in combination 
      with epidermal growth factor receptor inhibitors potently inhibits tumor cell 
      growth.
PG  - 1830-1836
LID - 10.7150/jca.69064 [doi]
AB  - The insulin-like growth factors (IGFs), IGF-1 and IGF-II, which bind to the IGF 
      receptor type 1 (IGF-1R) and the insulin receptor (IR), have been implicated in 
      the growth, survival, and metastasis of tumor cells. We have previously 
      identified a novel human monoclonal antibody (mAb), m708.5, which neutralizes 
      both human IGF-I and IGF-II, and potently inhibits phosphorylation of the IGF-1R 
      and the IR in breast cancer cells. In this study, m708.5 exhibited very strong 
      synergy with the epidermal growth factor receptor (EGFR) inhibitor gefitinib, and 
      synergy with chemotherapeutic agents in vitro against either neuroblastoma or 
      breast cancer cells. In xenografted models, the combination of m708.5 and 
      gefitinib significantly inhibited LAN-1 cell growth better than single agent 
      alone. Taken together, these results support the clinical development of m708.5 
      for solid tumors with potential for synergy with chemotherapy and EGFR 
      inhibitors.
CI  - (c) The author(s).
FAU - Ma, Guofang
AU  - Ma G
AD  - Key Laboratory for Molecular Enzymology and Engineering, Ministry of Education, 
      School of Life Sciences; Jilin University, Changchun, Jilin, China.
AD  - Engineering Laboratory for AIDS Vaccine, Jilin Universtiy, Changchun Jilin, 
      China.
FAU - Tan, Chengyue
AU  - Tan C
AD  - Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau, 
      China.
AD  - MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, 
      Macau SAR, China.
FAU - Shan, Yaming
AU  - Shan Y
AD  - Key Laboratory for Molecular Enzymology and Engineering, Ministry of Education, 
      School of Life Sciences; Jilin University, Changchun, Jilin, China.
AD  - Engineering Laboratory for AIDS Vaccine, Jilin Universtiy, Changchun Jilin, 
      China.
FAU - Shao, Ningyi
AU  - Shao N
AD  - Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau, 
      China.
AD  - MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, 
      Macau SAR, China.
FAU - Wang, Feng
AU  - Wang F
AD  - Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, 
      Beijing Institute of Technology, Beijing, China.
FAU - Dimitrov, Dimiter S
AU  - Dimitrov DS
AD  - Department of Medicine, Center for Antibody Therapeutics, University of 
      Pittsburgh, Pittsburgh, Pennsylvania, United States.
FAU - Wang, Liping
AU  - Wang L
AD  - Key Laboratory for Molecular Enzymology and Engineering, Ministry of Education, 
      School of Life Sciences; Jilin University, Changchun, Jilin, China.
AD  - Engineering Laboratory for AIDS Vaccine, Jilin Universtiy, Changchun Jilin, 
      China.
FAU - Zhao, Qi
AU  - Zhao Q
AD  - Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau, 
      China.
AD  - MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, 
      Macau SAR, China.
LA  - eng
PT  - Journal Article
DEP - 20220321
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC8990425
OTO - NOTNLM
OT  - EGFR
OT  - IGF-I
OT  - IGF-II
OT  - gefitinib
OT  - m708.5
OT  - monoclonal antibody
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2022/04/12 06:00
MHDA- 2022/04/12 06:01
PMCR- 2022/01/01
CRDT- 2022/04/11 05:17
PHST- 2021/11/15 00:00 [received]
PHST- 2022/02/25 00:00 [accepted]
PHST- 2022/04/11 05:17 [entrez]
PHST- 2022/04/12 06:00 [pubmed]
PHST- 2022/04/12 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - jcav13p1830 [pii]
AID - 10.7150/jca.69064 [doi]
PST - epublish
SO  - J Cancer. 2022 Mar 21;13(6):1830-1836. doi: 10.7150/jca.69064. eCollection 2022.